Allergy immunotherapy consistently performs well in the real world. The outcomes of this study based on the previous data from RCT for favorable efficacy and safety profiles of SQ SLIT tablets broaden the evidence for long-term, disease-modifying effects of the sublingual tablet.

Subgroup analysis of the REACT study was performed to investigate the realistic, long-term safety and efficacy of allergy immunotherapy (AIT): characterize the efficacy of drug administration routes of AIT (i.e. sublingual and subcutaneous), therapeutic allergen (grass, tree pollen and dust mite), AIT persistence, and SQ grass sublingual immunotherapy (SLIT) tablet.

An assessment of the preliminary outcome of allergic rhinitis (AR) prescriptions from the REACT Study; conducted during the years 2007 to 2017 was done amongst two subgroups, in people with AR with prescription and without prescription of allergic immunotherapy (control group). Anaphylaxis for two days or less following the initial AIT prescription was the safety endpoint. Up until samples had fewer than 200 respondents, subgroup follow-up was conducted.

In comparison with controls, SCIT and SLIT tablets had more decreases in AR prescriptions. Also, greater decreases in AR prescriptions were found for specific AIT (grass and dust mite) compared to controls, but then again there were considerably lesser decreases for tree pollen AIT.

The persistence to AIT was linked with more reductions in AR prescriptions compared to non-persistence. Constant reductions were observed for the SQ grass SLIT tablet for about 7 years when compared to controls. The incidence of severe allergic reactions (anaphylactic shock) was low, with no actions for SQ SLIT tablets.

These findings confirm the disease-altering outcomes seen in SQ grass SLIT-tablet randomized controlled studies and illustrate the long-term efficacy of AIT in the real-world. It also focuses on the significance of using novel evidence-based AIT products for AR conditions due to tree pollen.